These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 19399787

  • 21. [Procyanidins inhibit proliferation and promote apoptosis of the prostate cancer cell line LNCaP].
    Wu ZQ, Huang H, Ding XM, Luo RC.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):499-500. PubMed ID: 17545043
    [Abstract] [Full Text] [Related]

  • 22. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone.
    Hall CL, Dai J, van Golen KL, Keller ET, Long MW.
    Cancer Res; 2006 Sep 01; 66(17):8648-54. PubMed ID: 16951179
    [Abstract] [Full Text] [Related]

  • 23. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B, Zhang H, Wang J, Chen WZ, Li SH, Shi QG, Liang RX, Xie BX, Wu RQ, Qian XL, Yu L, Li QM, Huang CF, Zhou JG.
    Prostate; 2009 Aug 01; 69(11):1176-87. PubMed ID: 19415690
    [Abstract] [Full Text] [Related]

  • 24. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H.
    Cancer Epidemiol Biomarkers Prev; 2006 Feb 01; 15(2):217-27. PubMed ID: 16492908
    [Abstract] [Full Text] [Related]

  • 25. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
    Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, Nakatani T, Yoshimura R.
    Oncol Rep; 2007 Jul 01; 18(1):99-104. PubMed ID: 17549353
    [Abstract] [Full Text] [Related]

  • 26. Effect of calcitriol on prostate-specific antigen in vitro and in humans.
    Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K.
    Clin Cancer Res; 2006 May 01; 12(9):2812-6. PubMed ID: 16675575
    [Abstract] [Full Text] [Related]

  • 27. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate.
    Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H.
    Prostate; 2007 Jul 01; 67(10):1132-42. PubMed ID: 17492653
    [Abstract] [Full Text] [Related]

  • 28. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.
    Sánchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, Díaz-Laviada I.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):237-45. PubMed ID: 18343365
    [Abstract] [Full Text] [Related]

  • 29. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
    Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M.
    Res Commun Mol Pathol Pharmacol; 2004 Apr 28; 115-116():251-64. PubMed ID: 17564322
    [Abstract] [Full Text] [Related]

  • 30. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O.
    Clin Cancer Res; 2009 Oct 01; 15(19):6070-8. PubMed ID: 19789329
    [Abstract] [Full Text] [Related]

  • 31. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
    Zhang Y, Ma Y, Lu HP, Zhou XF, Xie Y, Gao JH, Liang CS.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 29; 88(29):2073-6. PubMed ID: 19080439
    [Abstract] [Full Text] [Related]

  • 32. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.
    Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH.
    Prostate; 2008 May 01; 68(6):610-9. PubMed ID: 18196550
    [Abstract] [Full Text] [Related]

  • 33. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
    Evans S, Dizeyi N, Abrahamsson PA, Persson J.
    Anticancer Res; 2009 Oct 01; 29(10):3917-24. PubMed ID: 19846929
    [Abstract] [Full Text] [Related]

  • 34. Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.
    Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z.
    Prostate; 2009 Apr 01; 69(5):538-47. PubMed ID: 19107848
    [Abstract] [Full Text] [Related]

  • 35. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
    Ben-Yosef R, Starr A, Karaush V, Loew V, Lev-Ari S, Barnea I, Lidawi G, Shtabsky A, Greif Y, Yarden Y, Vexler A.
    Prostate; 2007 Jun 01; 67(8):871-80. PubMed ID: 17440944
    [Abstract] [Full Text] [Related]

  • 36. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression.
    Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, Arai Y, Fukuda M.
    Glycobiology; 2005 Oct 01; 15(10):1016-24. PubMed ID: 15932919
    [Abstract] [Full Text] [Related]

  • 37. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation.
    Wang Q, Horiatis D, Pinski J.
    Prostate; 2004 Nov 01; 61(3):253-9. PubMed ID: 15368468
    [Abstract] [Full Text] [Related]

  • 38. The roles of epithelial-mesenchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immuno-compromised mice.
    Frost GI, Dudouet B, Lustgarten J, Borgström P.
    In Vivo; 2003 Nov 01; 17(5):377-88. PubMed ID: 14598599
    [Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
    Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S.
    Clin Cancer Res; 2009 Feb 01; 15(3):898-906. PubMed ID: 19188160
    [Abstract] [Full Text] [Related]

  • 40. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A, Reed MJ.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):251-8. PubMed ID: 18786604
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.